cyrilzakka/clinical-trials huggingface dataset:
Superior Vena Caval Obstruction (SVCO) - Management and Outcome

All patients with symptomatic malignant SVCO deemed suitable for treatment either with radiation therapy or by stenting will be eligible. They will receive whichever treatment is deemed most clinically appropriate. Symptomatic response, time to onset of palliation, duration of symptom control and survival will be assessed.


Eligibility Criteria:
Inclusion Criteria:

* Symptomatic clinical and radiological diagnosis of superior vena caval obstruction.
* Underlying histological diagnosis deemed appropriate for palliative radiotherapy as treatment by investigator. Patients with chemosensitive tumours such as small cell lung cancer (both untreated and recurrent), lymphoma and testicular tumours, will be eligible if radiation is deemed to be appropriate treatment.
Sexual Behavior Among Medical Students in Mexico

This study aims to identify factors that influence students to undertake or not sexually transmitted diseases screening tests and to have an actual outlook of how Mexican university students live their sexual life. Moreover, the investigators aim to identify potential epidemiological risks and challenges to achieve adequate prevention and control of sexually transmitted diseases in this population. This is a descriptive cross-sectional study conducted at a private university in Guadalajara, Jalisco, Mexico, from December 2019 to April 2020.

The investigators will invite the students to complete it and leave it in a black painted box to maintain privacy. The investigators will inquire if the participants considered having adequate knowledge about STDs, sexual intercourse onset, sexual behavior, number of sex partners, sexual orientation, use of condoms and contraceptives, sexual intercourse under the influence of alcohol or drugs, and reasons why students do not get sexually transmitted diseases screenings.

Eligibility Criteria:
Inclusion Criteria:

* University students currently attending medical school from 1st through 6th semester

Exclusion Criteria:

* Young adults not attending medical school
* Students out of the 1st - 6th-semester range
The Flashing Light-Induced Pupil Response (FLIPR) Glaucoma Study

This study is designed to investigate whether the pupil response to slowly flashing colored lights is significantly altered in patients with glaucoma, as compared to a control group of subjects without glaucoma.

The pupils inside the eyes constrict in response to light stimulation. Different classes of cells within the human retina initiate this response. Recent research suggests that one of the ganglion cell types involved in this pupil response is affected by glaucoma. By measuring pupil responses to different colored lights, the function of this class of cells can be evaluated quickly, and without touching the eye. An advantage of pupil testing strategies is that they do not require subjective feedback from the subject about what they can see, as is required for standard visual field tests that are used in the clinic.

The main aim of this study is to measure and compare the pupil constriction that occurs in response to flickering red and blue lights in patients with glaucoma versus matched control patients without glaucoma. In addition, the subjects will be asked questions about their quality of life and it will be determined whether issues related to quality of life correlate to alterations in the pupil responses.

Eligibility Criteria:
Inclusion Criteria:

* 18+ years old
* Diagnosed with glaucoma of known severity (cases only)
* Have a refractive error between +4.00 and -8.00 sphere power, and no more than 3.00 diopters of astigmatism
* Best corrected visual acuity of 20/40 or better in each eye
* Have open anterior chamber angles

Exclusion Criteria:

* Diagnosis of glaucoma of a type other than Primary Open Angle (cases only)
* History of having surgery or taking medications known to profoundly affect pupillary function or shape
* Visual Field defect (controls only)
* History of traumatic brain injury requiring hospitalization
* Pregnancy
* History of optic nerve disease other than glaucoma
* History of retinopathy
* History of unreactive pupils
* Presence of significant cataract
Esketamine vs Remimazolam for Postoperative Sleep Disturbance and Anxiety

To explore and compare the effects of esketamine and remimazolam on postoperative sleep disturbance in patients undergoing oocyte retrieval

Postoperative sleep disturbance (PSD) occur in the form of sleep deprivation, circadian rhythm disturbance, and structural abnormalities, and have a high incidence in patients undergoing surgery. Postoperative sleep disorders can lead to postoperative delirium and cognitive dysfunction, aggravate postoperative acute pain, and delay postoperative recovery.

Benzodiazepines have a certain sedative hypnotic anti-anxiety effect, and remimazolam as a new benzodiazepine, its sedative hypnotic anti-anxiety effect is worthy of further exploration. Esketamine is an N-methyl-D-aspartate(NMDA) receptor antagonist with analgesic and sedative effects, and is widely used in clinical treatment of refractory depression. For patients undergoing surgery, in addition to sedation and analgesia, whether the intraoperative use of esketamine has positive effects on postoperative sleep disturbance is worth exploring.

Eligibility Criteria:
Inclusion Criteria:

1. Age 18-45 years old;
2. American society of Aneshesiologists（ASA）physical status classification system is grade I-III;
3. Elective surgery is proposed
4. BMI of 19-30 kg/m2;
5. Patients who agreed to enroll in this study voluntarily

Exclusion Criteria:

1. Those who are known to be allergic to the drug ingredients in this study and their allergic constitution;
2. Allergic history of general anesthesia drugs, opioid drugs, non-steroidal drugs;
3. History of neurological diseases; History of chronic pain; Drug and alcohol addiction; A long history of opioid use; Opiates were given 48 hours before surgery
4. Coronary heart disease, bronchial asthma, severe hypertension, severe blood system dysfunction, liver and kidney function, electrolyte abnormalities;
5. Respiratory insufficiency, respiratory failure;
6. BMI\<18 kg/m2 or BMI\>30kg/m2;
7. Poor compliance, unable to complete the experiment according to the study plan; Participants who have participated in clinical trials of other drugs within the last 4 weeks;
8. Preoperative Pittsburgh Sleep Quality Index (PSQI) higher than 7
9. Any circumstances deemed unsuitable for inclusion by the researcher for any reason.
Pro- and Anti-inflammatory Cytokines in PCOS

The study will involve measurements and comparisons of the concentrations of pro-inflammatory cytokines: IL-6, TNF-α, IL-18, as well as anti-inflammatory cytokine IL-4 in women with polycystic ovary syndrome (PCOS) and insulin resistance, women with polycystic ovary syndrome without carbohydrate metabolism disorders, and women without PCOS (control group).

Polycystic ovary syndrome (PCOS) is the most common endocrinopathy among women of reproductive age, which, in addition to menstrual disorders and infertility due to anovulation, is characterized by insulin resistance (IR). The metabolic disturbances associated with PCOS contribute to a higher incidence of cardiovascular diseases and endometrial cancer prior to menopause. The severity of IR in women with PCOS is linked to abdominal obesity. There is an urgent need to identify more precise and universal markers of insulin resistance than the HOMA-IR index or glucose tolerance tests, which are intended to identify existing disorders rather than predispositions. Additionally, there is a need to investigate the balance of pro-inflammatory and anti-inflammatory parameters in PCOS and their relationship with insulin resistance, which is responsible for the development of adverse health complications.

The objective of this study is to measure and compare the concentrations of pro-inflammatory cytokines: IL-6, TNF-α, IL-18, and the anti-inflammatory cytokine IL-4 in women with polycystic ovary syndrome (PCOS) and insulin resistance, women with polycystic ovary syndrome without carbohydrate metabolism disorders, and women without PCOS (control group).

Tests will be conducted using immunoenzymatic methods (ELISA) and the Erba XL biochemical analyzer. The concentrations of the substances under investigation will be measured and compared among the three study groups. Statistical analysis will be performed using SPSS Statistics software.

Eligibility Criteria:
Inclusion Criteria:

* women aged 18-45 years

Exclusion Criteria:

* previous removal of at least one ovary
* treated diabetes of any type
* diagnosed and treated metabolic diseases
* diagnosed and treated autoimmune diseases
* diagnosed and treated autoinflammatory diseases
Doxorubicin Pharmacokinetic (PK) Study

This protocol is designed to obtain detailed information on the impact of body composition on the pharmacokinetic behavior of doxorubicin after a single intravenous dose in children 21 years of age or younger. There is no efficacy component. Approximately 9 children will be enrolled at Children's Hospital Boston. The information gained from this study could be very important in developing dosing strategies for doxorubicin in the obese patient population.


Eligibility Criteria:
Inclusion Criteria:

* Eligible patients will be \> 1 and ≤ 21 years old.
* All patients must be receiving chemotherapy that includes doxorubicin administered as an infusion of any duration \< 24 hours, on either a 1-day or 2-day schedule. This includes bolus and all short infusion schedules.
* All patients or their parents/legal guardians will provide informed consent/assent (as required by law) indicating their awareness of the investigational nature and the risks of this study according to the informed consent process.

Exclusion Criteria:

* Women who are known to be pregnant or lactating
* Patients with significant uncontrolled systemic illness
* Serum glutamic oxaloacetic transaminase (SGOT/AST), serum glutamic pyruvate transaminase (SGPT/ALT) \> 3 times the upper limit of normal tested within 14 days prior to infusion
* Bilirubin \> the upper limit of normal tested within 14 days prior to infusion
* Patients whose dose of doxorubicin is based on ideal body weight
* Patients who weigh \< 12 kilograms at time of screening
High Intensity Multi-Modal Exercise Training in Postmenopausal Women

in Pakistan 9.9 million people are osteoporotic and 7.2 million amongst them are women. Globally after every 3 seconds there is occurrence of fragility fracture.In Pakistan females carries different risk factors based on distinct culture, environment, diet and lifestyle. So there is dire need to conduct more high quality clinical trials at National level in order to establish strong evidence in favor of low cost but highly effective exercise protocols for such a significant public health issue.

In postmenopausal age, women bones get weak and easily fracture after 50years. In Pakistan every other female is silently suffering from this disease leading to bone, joint pain and disability. This project is innovatively designed first time in Pakistan to target weak bones of women with high intensity, progressive exercise training. The objectives of this study are to determine the effects of a high intensity multi-modal exercise training on bone mineral density and functional performance in postmenopausal women.

After initial screening based on history, subjective fracture risk calculations and subjective osteoporosis screening. Females fulfilling criteria and willing to participate in exercise trial will be recruited in the study. At baseline, DEXA scan will be done for Femoral and lumbar bone density. All performance based testing for functional performance outcome measures would be done at baseline, after 3 months \& after 6 months. Patient will be called twice a week for 8months and DEXA will be repeated after 8months of training. It is hypothesized that supervised exercise training will improve bone mineral density and functional performance in postmenopausal women with low bone mass.

Eligibility Criteria:
Inclusion Criteria:

* Postmenopausal Women, at least 3 years since last mensuration.
* Age: 45-70years
* Body mass index (BMI) \<30kg/m2
* Community ambulant without walking aid
* Good general health
* Willing for exercise therapy

Exclusion Criteria:

* History of fragility fracture in addition to BMD T-score of -2.5 or less
* MMSE \< 20
* Taking Hormone replacement therapy or steroids from last 1 year.
* Had participated in regular exercise for last 1 year
* Systemic illness: hyperthyroidism, hyperparathyroidism, Diabetes Mellitus, renal failure, any malignancy, extensive radiation exposure
* Any orthopedic injury/disorder hindering performance of exercise.
Cognitive Function After Radiation Therapy for Primary Brain Tumours

This study will assess cognitive function in patients with a primary brain tumour treated with radiation therapy (RT) to generate radio-sensitivity and volume effect parameters for the development of cognitive dysfunction. All types of brain tumours apart from glioblastoma will be included.

RT is fundamental in the treatment of primary brain tumours. RT contributes to improved local control and prolonged progression-free survival in patients with a broad range of tumour types. Irradiation to the normal brain may lead to cognitive impairments. Clarifying the nature and severity of impairment in adult RT-treated brain tumour patients, including region-specific effects, are important for optimal utilization of novel conformal RT technologies such as proton therapy.

The study is a prospective nationwide study including approximately 300 brain tumour patients from the Danish Center of Particle Therapy and the four Neuro Oncology Centers in Denmark.

The patients will be assessed with a comprehensive battery of standardized cognitive tests and complete a questionnaire (PRO's). They will do this prior to RT treatment and 1, 3, 5 and 10 years afterwards. The PRO's includes measures on quality of life, fatigue, sleep, depression, anxiety, and socio demographics. The standardized tests are: Trail making Test (TMT); Hopkins Verbal Learning Test (HVLT); Controlled Oral Word Association Test (COWAT) - Animals and S; Coding and Digit Span from WAIS-IV. The correlation between cognitive scores and RT dose-volume parameters to specific areas in the brain will be tested.

This study will elucidate the dose-response relationship in radiation-induced damage to substructures of the brain such as hippocampus, thalamus, temporal and frontal lobes that will allow the clinician to prioritize these structures in planning of proton radiotherapy.

Eligibility Criteria:
Inclusion Criteria:

* 18 years or older and Danish speaking.
* Performance status WHO 0-2
* Capable of cooperating on testing
* Tumour histology (WHO 2016 classification) of the following types: anaplastic astrocytoma (IDH mutant), diffuse astrocytoma (IDH-mutant), gemistocytic astrocytoma (IDH mutant), diffuse astrocytoma (NOS), oligodendroglioma, meningioma, medulloblastoma (NOS), pituitary adenoma, other brain tumours including skull base sarcomas

Exclusion Criteria:

* Glioblastoma
* Performance status 3-4 (Karnofsky Performances of 60 or less)
The Safety and Efficacy Study of HU-014 Versus Botox® in Subject With Moderate to Severe Glabellar Lines

A Phase I/Ⅱ Clinical Trial to Compare the Safety and Efficacy of HU-014 versus Botox® in Subject with Moderate to Severe Glabellar Lines


Eligibility Criteria:
Inclusion Criteria:

* Facial Wrinkle Scale (FWS) score \> 2 when Subject knits brow extremely

Exclusion Criteria:

* Volunteer who has history of any diseases following. (myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis etc.)
* From screening, Subject who get a plastic Surgery including fascioplasty, Prosthesis implantation within 6 Weeks
* Subject who has skin disorder including infection and scar on injection site
* Subject who takes a medication including skeletal muscle relaxants, Aminoglycoside, lincomycin, anticholinergic drug, benzodiazepine, benzamide etc.
* Subject who takes a medication including anticoagulant, antithrombotic drug except low dose aspirin (below 325 mg/day)
* Any condition that, in the view of the investigator, would interfere with study participation
QTc Study of Rosi XR in Healthy Volunteers

This study is a randomised double blind, parallel group, and will evaluate the effects of repeat oral doses of RSG- XR for 21 days on the QTc interval compared to placebo in a population of healthy adult males and females.

An extended release (XR) formulation of rosiglitazone maleate (RSG), a new formulation of rosiglitazone, is being investigated as a treatment for patients with mild to moderate Alzheimer's disease (AD).

This study is a randomised double blind, parallel group, and will evaluate the effects of repeat oral doses of RSG- XR for 21 days (due to the long half-life of the main metabolite M10) on the QTc interval compared to placebo in a population of healthy adult males and females between 18 and 45 years of age. Moxifloxacin, a drug with well-quantified QTc prolongation, will be included as a positive control in order to validate the ability of the study to detect small changes in QTc.

Eligibility Criteria:
Inclusion Criteria:

* Healthy male and female volunteers aged between 18 and 45
* Female of non child bearing potential or if of child bearing potential they must use adequate contraception for the duration of the study up until 14 days after the last dose
* Body weight greater than or equal to 45 kg and BMI within the range 19 - 32 inclusive
* Subjects must provide full written informed consent

Exclusion Criteria:

* Cardiac conduction abnormalities
* Any history of myocardial infarction, syncope, or cardiac arrhythmias or a history of uncontrolled hypertension or unstable heart disease
* Subjects with a systolic blood pressure outside the range of 90 to 150 mmHg or diastolic blood pressure outside the range of 50 to 100 mmHg
* Subjects with a personal or family history of QTc prolongation or unexplained cardiac arrest.
* Has a history of illicit drug use or alcohol abuse within the past year or a positive pre-study test for alcohol, cotinine, or drugs of abuse at Screening or prior to the start of dosing
* Alanine aminotransferase (ALT), aspartate aminotransferase (AST), or alkaline phosphatase values greater than 2.5 times the ULN, total bilirubin values \>1.5 times the upper limit of normal (ULN), or history of severe hepatobiliary disease (e.g. hepatitis B or C, or cirrhosis, Child-Pugh Class B/C)
* A positive test at Screening for Hepatitis B, Hepatitis C, or Human Immunodeficiency Virus (HIV)
* Use of any agents that are known to inhibit or induce cytochrome CYP3A4 enzymes within 7 days prior to the first dose of study drug (including foods or supplements such as grapefruit-containing products, mustard greens, kale, kohlrabi, broccoli, collard greens, brussel sprouts, watercress, charbroiled meats or St. John's Wort
* Use of any prescription or non-prescription drugs, in particular drugs known to inhibit or induce CYP2C8, vitamins (exceptions may be considered on a case-by-case basis with the GSK medical monitor), herbal and dietary supplements within fourteen days prior to the first dose of study drug
* Lactating or pregnant females
Safety and Efficacy Study of Isolagen TherapyTM in Treatment of Interdental Papillary Insufficiency

The purpose of this study is to evaluate the safety profile and the treatment effect of Isolagen TherapyTM in subjects with maxillary lesions who were treated in a previous study (IT-G-002, no NCT identification number)


Eligibility Criteria:
Inclusion Criteria:

* Subject must be 18-70 years of age
* Subject was treated in IT-G-002 (no NCT identification number)
* Subject has maxillary interproximal recession defects
* Natural teeth must be present on both sides of each area to be treated
* Negative pregnancy test and use of acceptable birth control (females of childbearing age)

Exclusion Criteria:

* Subjects who participated in other clinical trials within 30 days prior to enrollment
* Interproximal spaces including root grooves or furcations must not be involved
* Subjects with poor oral hygiene
* Subjects with a systemic condition, which would preclude periodontal treatment
* Subjects with acute infectious lesions in the treatment areas
* Subjects with open interproximal contact at study sites
* Subjects who must receive prophylactic antibiotics before dental procedures
* Subjects on chronic antibiotic or steroidal therapy
* Subjects with interproximal probing depths \> 3 mm around study lesions
* Subjects who smoke
* Subjects taking medications associated with the development of drug induced gingival hyperplasia
* Subjects with radiographic evidence of pathology
* Subjects with tooth mobility exceeding a score of 1
* Subjects with parafunctional habits and not wearing bite guard
* Subjects with interproximal spaces associated with teeth without an adequate zone of keratinized tissue
* Subjects where the etiology of the interproximal papillary recession has not been controlled
* Subjects who have received a crown or pontic on one or both teeth involved in the interproximal space to be treated
Obstructive Airways Diseases in Pulmonary Clinic (OADPC) Study

This is an observational study which aims to evaluate the possibility of using data from a capnography device to assess obstructive airway severity in both Chronic Obstructive Pulmonary Disease (COPD) and Asthma patients.

This is an observational study which aims to evaluate the possibility of using data from a capnography device to assess obstructive airway severity in both COPD and Asthma patients. The study will include adult asthma and COPD patients (age \>18). Patients will be enrolled on a continuous basis and will be monitored by capnograph and oximeter before and after lung function assessment and also during and after medical treatment.

Eligibility Criteria:
Inclusion Criteria:

1. Age \>18
2. Ability and willingness to participate the study and sign informed consent form
3. Asthma / COPD patients

Exclusion Criteria:

1. Pregnant women
2. Asthma or COPD patients with FEV1 \> 80%
3. Disability or unwillingness to undergo capnography measurement
4. Cannot be assessed for FEV1
5. Oxygen supply \>5 L/min
6. 6. Subjects that gone through LOBECTOMY OF LUNG in the last 5 years.
Efficacy and Safety Study of the HS-25 Combination With Atorvastatin in Subjects With Hypercholesterolemia in Coronary Heart Diseases

To determine the efficacy of HS-25 (20mg) in reducing low density lipoprotein-cholesterol (LDL-C) levels after a 12-week period of treatment in combination with Atorvastatin in subjects with hypercholesterolemia and coronary heart diseases; To determine the safety of HS-25 (20mg) combination with Atorvastatin in subjects with hypercholesterolemia and coronary heart diseases


Eligibility Criteria:
Inclusion Criteria:

* Diet control for 14 weeks, Atorvastatin 10mg once daily for 6 weeks or above;
* The average of both qualifying values must be in the range of 2.07 mmol/L to 3.36 mmol/L. Run-in (Visit 2 and Visit 3) and the Visit 3 value must be within 12% of the value at Visit 2, higher or lower;
* Must meet the one of diseases as following:

  1. Subjects who have stable coronary heart disease;
  2. Subjects who diagnosed ischemic stroke in stable condition;
  3. Subjects who diagnosed as Diabetes mellitus

Exclusion Criteria:

* history of Severe Endiocrine disease (for example Thyroid function abnormal);
* History of advanced cancer
* Arrhythmias need to be treated by medications history of Hemorrhagic stroke;
* Cardiac dysfunction;
* Unstable ASCVD;
* History of organ transplant;
* Hypersensitive to HS-25 or place;
* uncontrolled or new diagnosed diabetes mellitus;
* HCV and HBsAg positive